Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated
